Ultime notizie per Cardinal Health (NYSE:CAH) Azioni

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the us, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and McKesson, the three comprise well over 90% of the us pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CPRX

VRNA

Scopriamo i 3 titoli sanitari che potrebbero affrontare un crollo a causa di indicatori di mercato e RSI elevati.

Scopri i 3 titoli sanitari che potrebbero crollare ad agosto

Earnings

CSCO

OUST

SERV

Scopri i 5 titoli azionari da tenere d&#39;occhio oggi, 14 agosto 2024, con aggiornamenti su Brinker, Cisco e altri.

Pre-market: 5 titoli da monitorare oggi, 14 agosto 2024

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

UBS LUX MSC CANA ETF

Majorie Taylor Greene disclosed new stock transactions this week, which come as public efforts to ban members of Congress from trading continue to grow over <a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin">potential conflicts of interest.</a>
Here are the latest trades by the Republican House member from Georgia.
 What Happened: Greene has increased her frequency of trading disclosures <a href="https://www.benzinga.com/markets/equities/24/05/38611874/marjorie-taylor-greene-reveals-new-stock-trades-after-2-year-gap-berkshire-hathway-goldman-sachs">in recent months</a> with several large batches of stock purchases announced recently after a two-year hiatus of disclosures.
On Sept. 23, Greene disclosed her latest transactions, as reported by<a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene"> Benzinga's Government Trades page.</a>
Here are the stocks Greene bought, with each one disclosed as a value of $1,000 to $15,000:
<ul>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Berkshire Hathaway B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</li>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Southern Copper Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NASDAQ">SCCO</a>)</li>
<li>United Parcel Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
</ul>
Several of these purchases add to recent stakes taken by the representative, including shares of Berkshire Hathaway, Microsoft and CrowdStrike.
The disclosure by Greene did not report any sale transactions, which means the congresswoman continues to hold her Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares <a href="https://www.benzinga.com/general/social-media/24/08/40475137/djt-stock-hits-new-lows-since-trump-media-companys-public-debut-heres-how-much-marjorie-tayl">bought in October 2021.</a>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Greene disclosed buying Digital World Acquisition shares back in October 2021, the SPAC that took Donald Trump's media company public in March 2024.
The transaction was done with shares trading between $67.96 to $118.80. A tweet from UnusualWhales pins the purchase price at $94.20, meaning Greene is down significantly on her $15,000 to $50,000 purchase in the Trump-linked stock. Shares of DJT trade at $13.63 at the time of writing.
Greene buying CrowdStrike shares continues to be an area to watch as <a href="https://www.benzinga.com/general/politics/24/07/39585140/marjorie-taylor-greene-buys-cybersecurity-stock-owned-by-nancy-pelosi-why-trade-could-draw-red-f">Benzinga previously reported</a> the representative sits on the Subcommittee on Cybersecurity, Information Technology and Government Innovation, which operates under the House Committee on Oversight and Accountability.
With the latest stock transactions, Greene has increased her holdings in technology stocks along with placing bets on Warren Buffett to continue powering Berkshire Hathaway along after the stock hit a $1 trillion market capitalization.
Not many can say that their investing portfolios are betting on Donald Trump and Warren Buffett, but Greene can.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Government

Politics

CRWD

GOOG

INTC

LRCX

MSFT

SCCO

Marjorie Taylor Greene Stays Loyal To Trump, Keeps DJT Stock, Buys Into Warren Buffett's Berkshire In Latest Trades

Cardinal Health To Acquire Integrated Oncology Network For $1.115B, Expanding Navista Alliance With Over 100 Providers Across 50 Community-Based Sites In 10 States

Telix Selects Cardinal Health As A Commercial Radiopharmaceutical Distributor To Supply Finished Unit Doses Of Its PET Agent Zircaix For Imaging Of Kidney Cancer In US

Argus Research analyst David Toung maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $115 to $125.

Price Target

Analyst Ratings

Argus Research Maintains Buy on Cardinal Health, Raises Price Target to $125

The City of Baltimore, led by Mayor Brandon M. Scott, reached an $80 million settlement with Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) to resolve claims against the company for its role in the city&#8217;s opioid epidemic.
Under the agreement, Teva will pay an initial $35 million by the end of 2024, with the remaining amount due by July 1, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40754258/jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-s" rel="noreferrer noopener">JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability</a>.
The <a target="_blank" href="https://mayor.baltimorecity.gov/news/press-releases/2024-09-09-city-baltimore-reaches-80-million-deal-teva-pharmaceuticals-resolve" rel="noreferrer noopener">settlement</a> is part of Baltimore's broader litigation strategy against opioid manufacturers and distributors.
Previous settlements with AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Allergan, CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) have brought in $322.5 million in total recoveries.
The ongoing legal battle will proceed to trial on Sept. 16 against the remaining defendants, who were responsible for more than half of the opioids distributed in Baltimore.
Mayor Scott emphasized the city's decision to opt out of the national Teva settlement, which would have yielded only $11 million over 13 years. Instead, the new agreement brings in more than seven times that amount in under a year.
Baltimore secured more than three times the funds it would have received from global settlements.
Baltimore will dedicate $5 million to education and outreach about the 988 crisis helpline, $3 million to the Penn North Recovery Center and $2 million to BMore Power.
Additional funds will be administered following the framework detailed in the executive order to address the ongoing epidemic.
In July, Teva announced topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent <a href="https://www.benzinga.com/general/biotech/24/07/39843370/tevas-migraine-treatment-found-effective-for-children-as-young-as-6" target="_blank" rel="noreferrer noopener">patients aged 6-17</a>.
The trial met its primary endpoint with Ajovy achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo.
TEVA Price Action: Teva stock is down 1.43% at $17.55 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40793504/viridian-therapeutics-discloses-exciting-data-from-experimental-thyroid-eye-disease-candidate-say" target="_blank" rel="noreferrer noopener">Viridian Therapeutics Discloses &#8216;Exciting&#8217; Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety</a>.</li>
</ul>
Photo: Ralf Liebhold via Shutterstock

Biotech

Large Cap

Health Care

Legal

General

ABBV

TEVA

Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies

The three largest U.S. drug distributors have reached a settlement of $300 million to resolve claims from health insurers and benefit plans over their alleged role in fueling the opioid epidemic, according to court documents filed on Friday.
The settlement involves McKesson Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), Cencora Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>). The proposed class action settlement, disclosed in a federal court in Cleveland, Ohio, requires a judge&#8217;s approval.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/06/39546645/unitedhealths-optumrx-settles-opioid-prescription-claims-for-20m" rel="noreferrer noopener">UnitedHealth&#8217;s OptumRx Settles Opioid Prescription Claims for $20M</a>.
Reuters highlights that the settlement comes on the heels of a $21 billion agreement by the same companies to settle claims from state and local governments.
Those claims accused the distributors of failing to implement proper controls, which allowed large quantities of addictive painkillers to be diverted into illegal markets.
The new settlement addresses the claims of third-party payers, such as union funds, who bore the financial burden of overprescribed and overmarketed opioid medications and the subsequent treatment of opioid use disorder.
The distributors did not admit any wrongdoing as part of the settlement. The $300 million payment will be divided among the companies, with McKesson paying 38.1%, Cardinal Health and Cencora paying 30.9% and 31%, respectively.
The case is part of a broader wave of litigation against drug manufacturers, distributors, and pharmacies, seeking accountability for a nationwide opioid crisis that has claimed hundreds of thousands of lives over the past two decades.
These lawsuits have collectively resulted in over $50 billion in settlements, primarily with state and local governments.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40691948/praxis-precision-medicines-touts-encouraging-data-for-mid-stage-epilepsy-drug" target="_blank" rel="noreferrer noopener">Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug</a>.</li>
</ul>
Image via Shutterstock

Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers

Cardinal Health Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is a global pharmaceutical and medical products distributor serving over 100,000 hospitals. It&#39;s also the largest distributor of medical supplies and surgical products in the United States. Cardinal Health provides medical supplies and specialty therapeutics to 90% of the hospitals in the United States, as well as 60,000 pharmacies and over 10,000 specialty physician offices.
The rising trend in acute care utilization from emergency rooms, ambulatory and surgical care centers, and inpatient hospital visits has helped drive record results for the company. The stock is also a dividend aristocrat, having raised its dividend for nearly 40 consecutive years.
Cardinal Health operates in the medical sector with major healthcare services companies like McKesson Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>), Stryker Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>), and Cencora Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cor#NYSE">COR</a>).
<h2>Cardinal Health&#39;s Massive Portfolio and Reach </h2>
The company&#39;s professional products range from durable medical equipment to anesthesia supplies, personal protective equipment (PPE), lab supplies, and surgical equipment. It carries over 46,000 home healthcare products to over 3.4 million patients. Its digital ecosystem supports medication adherence to over 23 million patients and over 60 payers. The company offers numerous tailored services, including data and analytics, to improve cost efficiencies, workflows, and waste reduction for ambulatory surgery centers, hospitals, pharmacies, and labs. They even provide customer packaging solutions to pharmaceuticals through its 60,000-square-foot facility with automated and semi-automated equipment accommodating small and large-volume batches and projects in compliance with all FDA standards.
<h2>Cardinal Health: Expanding Its Specialty Business </h2>
Cardinal continues to expand its specialty business, which focuses on distributing and servicing specialty pharmaceuticals, pharmacies, and physician practices. It offers technology platforms that help manage inventory, track patient outcomes, manage reimbursement cycles, and improve efficiency for pharmacies and practices. Specialty therapeutics include a wide array of high-cost, complex medications that often require special storage, handling, and patient support programs. In January 2024, the company agreed to acquire Specialty Networks for $1.2 billion in cash to accelerate growth in its Specialty business. &nbsp;
<img alt="Cardinal Health CAH stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20240818185626_chartb-cah.jpg" style="height:750px; width:915px" />
<h2>CAH Stocks Forms a Cup and Handle Breakout Pattern </h2>
The daily candlestick chart for CAH illustrates a cup and handle breakout pattern. The cup lip line at $105.08 was tested on Aug. 8, 2024. The pullback formed the handle staging the rally into its earnings release. CAH gapped to the cup lip line and proceeded to break out higher after testing the support for two days. The daily relative strength index (RSI) has bounced to the 75-band. Pullback support levels are at $105.08, $102.81, $98.79, and $96.05.
<h2>Cardinal Health Beats Top and Bottom Line Estimates </h2>
The fiscal fourth-quarter 2024 earnings report indicated strong top- and bottom-line acceleration. Cardinal Health reported EPS of $1.84, which beat the consensus analyst estimates for $1.74 by 10 cents. Its non-GAAP operating earnings rose 14% to $605 million. Segment profit increases in the Global Medical Products and Distribution and Pharmaceuticals and Specialty Solutions segments primarily drove the growth. Revenues grew 12.1% YoY to $59.87 billion, which also beat the consensus analyst estimate of $58.74 billion.
Fiscal 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectively. Fiscal full-year 2024 revenues rose 11% YoY to $226.8 billion. Full-year non-GAAP diluted EPS rose 29% to $7.53.
<h2>Cardinal Health Raises Its Guidance </h2>
The company issued upside fiscal full-year 2025 non-GAAP EPS of $7.55 to $7.70 versus $7.53 consensus estimates, raising it from previous guidance of $7.50. Full-year revenue is expected to grow 10% to 12% YoY. Its Pharmaceutical and Specialty Solutions segment is expected to see revenues decline 4% to 6% YoY. Its Global Medical Products and Distribution (GMPD) segment is expected to see 3% to 5% revenue growth. Other revenue is expected to grow 10% to 12% YoY.
Cardinal Health CEO Jason Hollar commented, &quot;We delivered robust cash flow generation, continued profit growth in the Pharmaceutical and Specialty Solutions segment and significant improvement driven by our GMPD Improvement Plan. We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance.&quot;
CAH analyst ratings and price targets are at MarketBeat. There are 12 analyst ratings on CAH stock, comprised of seven Buys, two Holds, and one Sell. Consensus analyst price targets point to a 7% upside at $117.45.
The article &quot;<a href="https://www.nasdaq.com/articles/cardinal-health-soars-americas-leading-acute-care-supplier">Cardinal Health Soars as America&#39;s Leading Acute Care Supplier</a>&quot; first appeared on MarketBeat.

Guidance

Dividends

Cardinal Health Soars as America's Leading Acute Care Supplier

JP Morgan analyst Lisa Gill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $111 to $123.

JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $123

Cardinal Health Announced That Its Plans To Open A New Distribution Center In Walton Hills, Ohio, Supporting Its U.S. Medical Products And Distribution Business

Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Hold and raises the price target from $115 to $119.

Deutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $119

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) has outperformed the market over the past 5 years by 6.06% on an annualized basis producing an average annual return of 19.81%. Currently, Cardinal Health has a market capitalization of $26.35 billion. 
Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,485.05 today based on a price of $108.05 for CAH at the time of writing.
<h3>Cardinal Health's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723820577_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cardinal Health Stock In The Last 5 Years

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $120 to $125.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $125

Wells Fargo analyst Stephen Baxter maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Underweight and raises the price target from $95 to $101.

Wells Fargo Maintains Underweight on Cardinal Health, Raises Price Target to $101

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $114 to $119.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $119

Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b">fourth quarter on Wednesday.</a>
Cardinal Health reported fourth-quarter 2024 adjusted EPS of $1.84, up 29% year over year, beating the consensus of $1.73.
Sales increased 12% to $59.87 billion, beating the consensus of $58.64 billion. The pharmaceutical segment revenue increased 12% to $55.6 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
Cardinal Health raised its fiscal year 2025 adjusted EPS guidance to $7.55-$7.70 from the preliminary outlook of at least $7.50 versus the consensus of $7.53.
The company updated its Pharmaceutical and Specialty Solutions segment profit growth outlook to 1%-3% growth from at least 1%. For the Global Medical Products and Distribution segment, the company expects revenue growth of 3%-5%. Overall revenue is expected to grow between 10%-12%.
"We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance," said Jason Hollar, CEO of Cardinal Health.
Cardinal Health shares closed at $106.36 on Wednesday.
These analysts made changes to their price targets on Cardinal Health following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> maintained Cardinal Health with an Outperform and raised the price target from $130 to $137.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ece538c4a1e100001de8a1a/elizabeth-anderson">Evercore ISI Group analyst Elizabeth Anderson</a> maintained Cardinal Health with an In-Line and boosted the price target from $105 to $115.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40393013/pfizer-conagra-brands-and-2-other-stocks-insiders-are-selling">Pfizer, Conagra Brands And 2 Other Stocks Insiders Are Selling</a></li>
</ul>
Considering buying CAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-1024x574.png" alt="" class="wp-image-496733" style="width:414px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings

Evercore ISI Group analyst Elizabeth Anderson maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a In-Line and raises the price target from $105 to $115.

Evercore ISI Group Maintains In-Line on Cardinal Health, Raises Price Target to $115

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our a<a href="https://www.benzinga.com/analyst-stock-ratings">nalyst ratings page.</a>
<ul>
<li>Rosenblatt raised the price target for Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) from $65 to $69. Rosenblatt analyst Mike Genovese maintained a Buy rating. Lumentum shares fell 1.5% to close at $45.53 on Wednesday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $250 to $252. Piper Sandler analyst Paul Newsome maintained an Overweight rating. Progressive shares gained 5.4% to close at $234.34 on Wednesday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Century Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) price target from $11 to $9. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Century Therapeutics shares fell 5.5% to close at $1.56 on Wednesday. <a href="https://www.benzinga.com/quote/IPSC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from $200 to $130. Wells Fargo analyst Michael Turrin downgraded the stock from Overweight to Equal-Weight. Snowflake shares gained 0.2% to close at $127.30 on Wednesday. <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) price target from $56 to $58. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Cisco shares gained 0.2% to close at $45.44 on Wednesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs increased The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) price target from $199 to $204. Goldman Sachs analyst Alex Scott maintained a Buy rating. Allstate shares gained 5.2% to close at $180.95 on Wednesday. <a href="https://www.benzinga.com/quote/ALL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS increased the price target for Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from $76 to $90. UBS analyst Danielle Antalffy upgraded the stock from Sell to Neutral. Medtronic shares fell 0.6% to close at $81.74 on Wednesday.<a href="https://www.benzinga.com/quote/MDT/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Citigroup cut Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) price target from $170 to $155. Citigroup analyst Asiya Merchant maintained a Buy rating. Dell shares gained 3% to close at $102.95 on Wednesday. <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) price target from $130 to $137. Baird analyst Eric Coldwell maintained an Outperform rating. Cardinal Health shares rose 3.7% to close at $106.36 on Wednesday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) price target from $21 to $24. Deutsche Bank analyst Brian Bedell upgraded the stock from Hold to Buy. Robinhood shares gained 1.3% to close at $18.65 on Wednesday. S<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">ee how other analysts view this stock.</a></li>
</ul>
Read Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">Jim Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>
Considering buying Robinhood stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-1024x571.png" alt="" class="wp-image-496664" style="width:511px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115.png 1240w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

DELL

HOOD

IPSC

LITE

SNOW

Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday

Baird analyst Eric Coldwell maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Outperform and raises the price target from $130 to $137.

Baird Maintains Outperform on Cardinal Health, Raises Price Target to $137

The July consumer inflation report released Wednesday confirmed a continued cooling trend in price increases across the economy, with the headline Consumer Price Index (CPI) coming in at 2.9% year-over-year, slightly below both the <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40365730/july-inflation-rate-falls-more-than-expected-supports-hopes-for-large-fed-rate-cu">previous and expected 3%. </a>
Core inflation, which excludes food and energy, also saw a modest decline from 3.3% to 3.2% year-over-year, aligning with economists&#8217; forecasts.
For investors, this signals that the Federal Reserve may have the green light to cut interest rates in September. However, the odds of a 25 basis point hike are slightly higher than those of a 50 basis point cut.
Wall Street had a mixed response to the data. Major indices initially rose around 10 a.m. E.T. before flattening out by midday trading in New York.
Both S&amp;P 500 and Nasdaq 100 are striving to secure their fifth consecutive sessions in the green.
Financial stocks outperformed among the 11 sectors of the S&amp;P 500. The biggest laggards were communication services, weighed down by a decline in Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), and consumer discretionary, dragged by Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Starbucks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>).
Long-dated Treasury yields fell by 4 basis points, boosting the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) by 0.6%.
The U.S. dollar index, as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), remained steady, while gold eased by 1%.
Oil prices, tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), declined by 1.1%, marking the second consecutive session of losses.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dropped 2.4% to $59,100.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,894.49</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,442.32</td>
<td>0.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,967.78</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,081.22</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 0.1% higher to $542.64.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.4% to $399.25.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) eased 0.1% to $461.91.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 0.9% to $206.01.</li>
<li>The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up by 0.8%. The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down by 0.8%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) surged 7.7% after the company announced it would be acquired by Mars in an all-cash deal valued at $35.9 billion.</li>
<li>Alphabet Inc. fell nearly 3% after reports that the U.S. Department of Justice may break up Google following a recent ruling that it monopolized the online search market.</li>
<li>Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) jumped over 4% after reporting that total client assets reached $9.572 trillion in July, up 16% year-over-year and 2% from June, with core net new assets surging 112% to $29 billion compared to July 2023.</li>
<li>Other financial stocks marking strong gains on Wednesday included The Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), The Progressive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) and Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) up 5%, 4.8% and 3.2%, respectively.</li>
<li>Stocks moving on earnings report were Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 4%, Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>), down 14% and Performance Food Group Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) up 8%. </li>
<li>Those reporting after the close include Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>).</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40370641/mortgage-applications-rocket-by-16-8-notch-strongest-weekly-increase-in-1-5-years-homebuyers-too">Mortgage Applications Rocket By 16.8%, Notch Strongest Weekly Increase In 1.5 Years: &#8216;Homebuyers Took The Opportunity To Refinance&#8217;</a></li>
</ul>
This photo was created using artificial intelligence MidJourney.

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Treasuries

Econ #s

Economics

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

GOOGL

PFGC

SBUX

SCHW

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

PowerShares DB US Dollar Index Bullish Fund

Select Sector SPDR-Consumer Discretionary

Wall Street Battles For Fifth Day Of Gains As Inflation Cools, Gives Green Light To Rate Cuts; Financials Outperform: What's Driving Markets Wednesday?

The July Consumer Price Inflation report made another step toward the Federal Reserve&#8217;s 2% target, though less pronounced than June&#8217;s, sustaining optimism for <a href="https://www.benzinga.com/topic/inflation">imminent interest rate cuts.</a>
Last month, a basket of goods and services purchased by U.S. consumers rose by 2.9% year-over-year, slightly below the previous and expected 3%, marking the fourth consecutive decline in annual inflation and the <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40365730/july-inflation-rate-falls-more-than-expected-supports-hopes-for-large-fed-rate-cu">lowest rate since March 2021.</a>
The annual core inflation rate also eased as anticipated, from 3.3% to 3.2%, the lowest since April 2021. 
However, the July report was marred by an increase in the shelter component, which, due to its significant weight in the basket, accounted for about 90% of the headline inflation rise.
The decline in annual inflation rates wasn&#8217;t sufficient to bolster expectations for a 50-basis-point rate cut in September. 
Market-implied probabilities for such a substantial cut dropped from 50% to 43% following the report, while the likelihood of a smaller 25-basis-point cut increased to 57%.
<h3 class="wp-block-heading">Market Reactions: Stocks Rise, Yields Steady, But Dollar Strengthens Against Yen</h3>
The July inflation data sparked a positive reaction in stocks, especially in the tech sector, with small caps outperforming their larger-cap counterparts. Treasury yields remained largely stable, while the U.S. dollar gained ground against the low-yielding Japanese yen.
Here are the premarket price reactions of the following exchange-traded funds (ETFs) to the inflation data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.2% at 09:10 a.m. in New York. Major premarket gainers were Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) and Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 7.2% and 5.5% respectively. </li>
<li>The tech-heavy Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.3%. Top gainers were Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) and Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) up 3.1% and 3%, respectively. </li>
<li>Semiconductors were the strongest-performing industry, with the VanEck Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>) up 0.9%. Micron Technology Inc. and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) led gains, with the latter up 2.1%. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 0.5%, with Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) and AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) making the larger gains in the premarket, up 16% and 13%, respectively. </li>
<li>The Invesco CurrencyShares Japanese Yen Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXY#NYSE">FXY</a>) fell 0.2%.</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/08/40355203/stocks-now-dismiss-recession-fears-but-bond-markets-tell-investors-to-stay-on-alert">Stocks Now Dismiss Recession Fears, But Bond Markets Tell Investors To Stay On Alert</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Small Cap

Federal Reserve

ANAB

ASML

VSCO

S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday

Deutsche Bank analyst George Hill maintained a Hold rating on Cardinal Health (CAH – Research Report) today and set a price target of $119.00. The ...

Deutsche Bank  Sticks to Its Hold Rating for Cardinal Health (CAH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Thermo Fisher (TMO – Research Report), Cardinal Heal...

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Cardinal Health (CAH) and Sanofi (OtherSNYNF)

Pioneer Balanced ESG Fund Q2 2024 Performance And Market Commentary

Pioneer Global Sustainable Equity Fund Q2 2024 Performance And Market Commentary

Dividend Champion, Contender, And Challenger Highlights: Week Of September 29

Investing in value stocks is appealing now due to their strong long-term performance and affordability, as interest rates decline and inflation stabilizes, providing a lower-risk opportunity before Wall Street takes notice. Hence, it may be wise to add fundamentally strong value stocks like Stellantis (STLA), Centene (CNC), and Cardinal Health (CAH) to one's portfolio now. Read on… Value stocks are increasingly attractive now due to their historically strong long-term performance, especially as interest rates decline. With inflation stabilizing and many stocks facing potential overvaluation, value stocks present a lower-risk opportunity for investors seeking reliable returns.
Therefore, investors could consider buying fundamentally strong value stocks such as Stellantis N.V. (<a href="https://stocknews.com/stock/STLA/">STLA</a>), Centene Corporation (<a href="https://stocknews.com/stock/CNC/">CNC</a>), and Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>) for their discounted valuations and solid fundamentals, before Wall Street catches on.
U.S. inflation is decelerating, contributing to economic stability. Gross domestic product (GDP) grew at an annualized <a href="https://www.reuters.com/markets/us/us-second-quarter-economic-growth-unrevised-gdi-revised-sharply-higher-2024-09-26/">3.0% in Q2 2024</a>, while gross domestic income (GDI) surged to a revised 3.4%. These positive trends reflect a balanced economic environment with improved corporate profits, reduced inflationary pressures, and stronger consumer spending.
Despite ongoing uncertainties, the recent <a href="https://www.forbes.com/advisor/investing/fed-rate-cut-impact-prices/">50 basis point rate cut</a> by the Fed has the potential to foster greater economic stability, increase profits through reduced borrowing costs, and enhance investor confidence. This environment makes undervalued stocks particularly appealing, as they stand to gain from improved earnings potential and a more positive market sentiment.
Considering these trends, let's assess the fundamentals of the abovementioned value stocks.
Stellantis N.V. (<a href="https://stocknews.com/stock/STLA/">STLA</a>)
Headquartered in Hoofddorp, the Netherlands, STLA designs, manufactures, distributes, and sells automobiles and light commercial vehicles, engines, transmission systems, metallurgical products, mobility services, and production systems worldwide.
On September 30, 2024, STLA announced that Leapmotor International has opened orders for the T03 and C10 electric vehicles in Europe through STLA's brand dealers. This joint venture aims to expand global sales of affordable, high-tech electric vehicles, with deliveries expected later this year.
On September 17, 2024, STLA inaugurated its global commercial vehicles hub at Mirafiori Automotive Park 2030 in Turin, Italy, to streamline cross-brand functions and strengthen leadership in the commercial vehicle market. STLA Pro One aims to enhance efficiency and global operations, with commercial vehicles accounting for one-third of the company's total net revenue.
In terms of forward non-GAAP <a href="https://www.investopedia.com/terms/p/price-earningsratio.asp">P/E</a>, STLA's 3.48x is 80% lower than the 17.39x industry average. Its 1.57x forward EV/EBITDA is 84.8% lower than the 10.36x industry average. Likewise, its 2.28x forward EV/EBIT is 85.2% lower than the 15.44x industry average.
STLA's net revenues for the first half ended June 30, 2024, stood at €85.02 billion ($94.91 billion). Its net profit attributable to the owners of the parent was €5.62 billion ($6.27 billion), and its adjusted operating income came in at €8.46 billion ($9.44 billion). Furthermore, the company's adjusted EPS was €2.36.
Street expects STLA's EPS and revenue for fiscal 2025 to increase 12.6% and 4.9% year-over-year to $5.20 and $196.98 billion, respectively. Over the past month, the stock has declined 4.3% to close the last trading session at $16.06.
STLA's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect robust prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
STLA is ranked #14 out of 54 stocks in the <a href="https://stocknews.com/category/auto-vehicle-makers/">Auto &amp; Vehicle Manufacturers</a> industry. It has an A grade for Value and a B for Stability. To see STLA's Growth, Momentum, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/STLA/">click here</a>.
Centene Corporation (<a href="https://stocknews.com/stock/CNC/">CNC</a>)
CNC operates as a healthcare enterprise that provides programs and services to underinsured and uninsured families, commercial organizations, and military families. The company operates through segments including Medicaid, Medicare, Commercial, and Other.
On September 23, 2024, CNC's subsidiary, Health Net, was selected to provide managed dental care services for Medi-Cal beneficiaries in Los Angeles and Sacramento counties under a new 54-month contract starting July 1, 2025. Health Net will serve nearly 385,000 members in these counties.
On September 4, 2024, CNC's subsidiary, Iowa Total Care, was awarded a four-year statewide Medicaid contract by the Iowa Department of Health and Human Services to continue providing Medicaid managed care services under the Iowa Health Link program. The contract begins July 1, 2025, with a potential two-year extension.
In terms of forward non-GAAP PEG, CNC's 1.38x is 30.1% lower than the 1.97x industry average. Likewise, its 10.92x forward non-GAAP P/E is 49.9% lower than the 21.78x industry average. Also, its 0.25x forward EV/Sales is 93.2% lower than the 3.69x industry average.
In the fiscal second quarter that ended June 30, 2024, CNC's total revenues rose 5.9% year-over-year to $39.84 billion. Likewise, its earnings from operations rose 5% from the year-ago value to $1.23 billion. The company's adjusted net earnings and adjusted EPS increased 11.1% and 15.2% over the prior-year quarter to $1.28 billion and $2.42, respectively.
For the quarter ending September 30, 2024, CNC's revenue is expected to increase marginally year-over-year to $38.08 billion. Its EPS for the quarter ending December 31, 2024, is expected to rise 45.8% year-over-year to $0.66. CNC surpassed the Street EPS estimates in each of the trailing four quarters. Over the past three months, the stock has gained 10.7% to close the last trading session at $74.58.
CNC's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Value and a B for Growth and Quality. Within the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry, it is ranked #2 out of 10 stocks. To access the additional POWR Ratings of CNC for Momentum, Stability, and Sentiment, <a href="https://stocknews.com/stock/CNC/">click here</a>.
Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>)
CAH operates as a healthcare services and products company internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and home-based patients. The company operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution.
On September 20, 2024, CAH announced its agreement to acquire Integrated Oncology Network (ION) for $1.12 billion in cash. The acquisition will expand CAH's Navista oncology practice alliance, adding over 100 providers across more than 50 community-based sites in 10 states.
On August 21, 2024, CAH announced plans to open a new 249,000-square-foot distribution center in Walton Hills, Ohio, by spring 2025. The facility will feature advanced technology and automation to enhance medical product distribution efficiency and customer service.
In terms of forward Price/Sales, CAH's 0.12x is 96.8% lower than the 3.78x industry average. Its 10.53x forward EV/EBIT is 37.6% lower than the 16.89x industry average. Likewise, its 14.40x forward non-GAAP P/E is 33.9% lower than the 21.78x industry average.
CAH's revenue for the fourth quarter, which ended on June 30, 2024, increased 12.1% year-over-year to $59.87 billion. Its non-GAAP gross margin rose 5.5% over the prior-year quarter to $1.88 billion. For the same quarter, the company's non-GAAP net earnings and non-GAAP EPS were $450 million and $1.84, respectively, up by 22.6% and 28.7% compared to the prior-year quarter.
Analysts expect CAH's EPS for the quarter ending March 31, 2025, to increase 5% year-over-year to $2.18. Its revenue for fiscal 2026 is expected to grow 8.2% year-over-year to $234.25 billion. It surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past year, CAH's stock has gained 24.7% to close the last trading session at $109.79.
CAH's POWR Ratings reflect this positive outlook. CAH has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Growth and Value and a B for Stability. Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> sector, it is ranked #3 out of 60 stocks. To access additional grades for CAH's Momentum, Sentiment, and Quality, <a href="https://stocknews.com/stock/CAH/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
STLA shares were trading at $13.96 per share on Monday afternoon, down $2.10 (-13.08%). Year-to-date, STLA has declined -40.14%, versus a 21.21% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/stla-cnc-cah-3-value-stocks-to-buy-now-before-wall-street-catches/>3 Value Stocks to Buy Now Before Wall Street Catches On</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Value Stocks to Buy Now Before Wall Street Catches On

Shelton Equity Income Strategy Q2 2024 Commentary

If I Had To Invest $150,000 Right Now, Here's What I Would Buy

AAPL

ACWI

AMAT

AMZN

AVGO

BABA

BABAF

BPOP

CADE

CFFI

CHCO

CHRW

CMCSA

CTBI

CTSH

CUBE

EBAY

ERIE

EXPE

FFIN

FISI

FMAO

FOXA

FTNT

FULT

FUNC

GAIN

GILD

HAGHY

HBNC

HLNE

HNSDF

HWBK

INDB

INGR

LULU

MBIN

MORN

MSCI

NTAP

NVDA

PRYMF

PRYMY

PSTG

QCOM

QQQM

RGLD

RYDAF

SCHD

SCHG

SCVL

SFBS

SFNC

SHEL

SNYNF

SPLG

SPTN

SSNC

STLA

STLD

SWBI

SYBT

THFF

TRGP

TRMB

UBSI

ULTA

UMBF

UTMD

VICI

VRSN

WASH

WSBC

Press Releases

Cardinal Health Board of Directors Approves Increase to Quarterly Dividend

Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2024 on August 14

Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance

Comments

Cardinal Health

Notizie

Ultime notizie per Cardinal Health (NYSE:CAH) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO